Becton Dickinson (NYSE:BDX) said today is once again extending its exchange offering for up to $1.1 billion in outstanding C. R. Bard (NYSE:BCR) notes from July 3 to August 1. The company is offering exchanges for approximately $500 million for 4.4% Bard note due 2021, $500 million for 3% notes due 2026 and $149.8 million in 6.7% notes […]
C.R. Bard
Medtech M&A: The 10 biggest deals so far in 2017
Over the past several years, the healthcare industry as a whole has experienced an abundance of mergers and acquisitions – major players are buying up their peers in deals ranging from millions to billions. The trend is continuing, and the healthcare playing field continues to be shaped by these mega-transactions. For the medical device industry, […]
Here are the top 5 medtech stories of mid-2017
The middle of 2017 is shaping up to be a continued whirlwind of activity for medtech. FDA is getting used to its new leadership but is facing a continued lack of clarity on user fees and UDIs. Industry is seeing a deeper consolidation in medical supplies, exemplified in Cardinal Health’s purchase of patient recovery supplies from […]
Bard wins FDA approval for LifeStream covered iliac stent
C.R. Bard (NYSE:BCR) said today that it won pre-market approval from the FDA for its LifeStream covered iliac stent for treating peripheral artery disease. The PMA covers the treatment of atherosclerotic lesions in common and external iliac arteries with diameters of 4.5mm to 12.0mm and lesion lengths of up to 100mm, Murray Hill, N.J.-based Bard said. […]
Bard shareholder looks to scuttle $24B merger with BD
A shareholder of C.R. Bard (NYSE:BCR) sued yesterday to stop a $24 billion merger with Becton Dickinson (NYSE:BDX), arguing that the price tag is too low and that the sale process was flawed and seeking class-action status for the suit. Plaintiff Richard Maser filed the lawsuit in the U.S. District Court for New Jersey, seeking to […]
Bard, Covidien settle more than 130 pelvic mesh cases
C.R. Bard (NYSE:BCR) and several subsidiaries of Medtronic (NYSE:MDT) unit Covidien settled more than 130 product liability lawsuits brought over pelvic mesh products. The lawsuits were part of multi-district litigation being overseen in the U.S. District Court for Southern West Virginia. last week and yesterday Judge Joseph Goodwin dismissed 134 of the cases with prejudice “because all […]
Anti-trust regulators want more from BD, Bard on $24B merger
Becton Dickinson & Co. (NYSE:BDX) and C.R. Bard (NYSE:BCR) said last week that the U.S. Federal Trade Commission wants more information on their pending $24 billion merger. The move adds 30 days to the timeline for closing the $317-per-share deal, the companies said, but the acquisition is still slated to close in the fall. “BD and Bard […]
BD extends exchange offer for Bard notes
Becton Dickinson (NYSE:BDX) said today it will extend its exchange offer for up to $1.1 billion in outstanding C. R. Bard (NYSE:BCR) notes from June 5 to July 3. The company is offering exchanges for approximately $500 million for 4.4% Bard note due 2021, $500 million for 3% notes due 2026 and $149.8 million in 6.7% notes due 2026. […]
AngioDynamics levels anti-trust suit against Bard over catheter tip locators
AngioDynamics (NSDQ:ANGO) said it leveled an anti-trust lawsuit against C.R. Bard (NYSE:BCR), alleging that the larger company illegally ties the sales of its peripherally inserted central catheters to its tip location devices. The lawsuit, filed today in the U.S. District Court for Northern New York, accuses Bard of maintaining its dominant position in the tip location market by only […]
Over-allotments take BD offering to nearly $5B
The underwriters of a $4.5 billion offering by Becton Dickinson (NYSE:BDX) exercised their over-allotment options, the medical device giant said today, taking the total proceeds to $4.95 billion. Franklin Lakes, N.J.-based BD plans to use the proceeds to help defray the cost of its $24 billion acquisition of C. R. Bard (NYSE:BCR). The company plans to float $2.25 billion worth of […]
BD prices $4.5B offering for Bard acquisition
Becton Dickinson (NYSE:BDX) today priced a $4.5 billion offering it plans to use to help finance its $24 billion acquisition of C. R. Bard (NYSE:BCR). The Franklin Lakes, N.J.-based medical products leviathan said it plans to float $2.25 billion worth of stock at $176.50 per share and $2.25 billion of convertible shares at $50.00 per share. The offering includes over-allotment options of […]